Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SNT-5505,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Syntara Announces Positive Interim Data in Phase 2 Study of SNT-5505 in Myelofibrosis
Details : SNT-5505 is a lysyl oxidase inhibitor small molecule drug candidate, which is currently being evaluated in combination with ruxolitinib for the treatment of myelofibrosis.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2024
Lead Product(s) : SNT-5505,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable